IRVING, Texas, March 20, 2012 /PRNewswire/ -- Novation, the leading health care supply contracting company, announces the release of its most recent Transcatheter Cardiovascular Therapeutics Report. This report is produced by Novation's cardiology staff and is intended to help VHA, UHC and Provista members understand and prepare for new cardiology technologies.
The Novation cardiology team compiled this report following their attendance late last year at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. The TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and the latest advances in current therapies and clinical research. The conference also showcases technologies and devices not yet available in the United States.
By attending the TCT meeting and learning about new trends and devices, the Novation cardiovascular team can advise members about the impact of upcoming technologies before they are approved by the U.S. Food and Drug Administration.
Novation's report focuses on several emerging technologies and trends. Areas of focus in this report include transcatheter aortic valve replacement, high blood pressure therapy, drug-eluting balloons, and bioabsorbable coronary stents, as well as coronary, peripheral vascular, structural heart, and heart rhythm products and technology trends.
Some of the devices, such as the percutaneous heart valves, have recently been approved. Other products, such as the drug-eluting balloon, bioabsorbable coronary stent and renal denervation, are in clinical trials and device development, but demonstrate promising early results. This report highlights these and other new cardiovascular devices in a condensed format.
"The intent of our report is to provide clinical and economic highlights of these new technologies that have a high probability of impacting the member hospitals we serve," said Mic